-
Cingulate Inc NASDAQ:CING Cingulate Inc. is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where its PTR technology may be employed to develop future product candidates, such as anxiety disorders.
Location: Kansas City, Kansas, United States | Website: https://www.cingulate.com/ | Industry: | Sector:
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
8.376M
Cash
12.21M
Avg Qtr Burn
-4.613M
Short % of Float
2.47%
Insider Ownership
2.81%
Institutional Own.
2.41%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CTx-1301 Details Attention deficit hyperactivity disorder | NDA Submission | |
CTx-1302 Details Mental health, Attention deficit hyperactivity disorder | Phase 1/2 Initiation | |
CTx-2103 (buspirone) Details Mental health, Anxiety Disorders | IND Submission |